Enanta Pharmaceuticals (ENTA) Stock Forecast, Price Target & Predictions
ENTA Stock Forecast
Enanta Pharmaceuticals stock forecast is as follows: an average price target of $65.67 (represents a 463.69% upside from ENTA’s last price of $11.65) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ENTA Price Target
The average price target for Enanta Pharmaceuticals (ENTA) is $65.67 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $87.00 to $54.00. This represents a potential 463.69% upside from ENTA's last price of $11.65.
ENTA Analyst Ratings
According to 3 Wall Street analysts, Enanta Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ENTA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Enanta Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 09, 2022 | - | H.C. Wainwright | $56.00 | $41.96 | 33.46% | 380.69% |
| Nov 22, 2022 | - | RBC Capital | $54.00 | $46.40 | 16.38% | 363.52% |
| Jul 29, 2022 | Yasmeen Rahimi | Piper Sandler | $87.00 | $51.27 | 69.67% | 646.78% |
The latest Enanta Pharmaceuticals stock forecast, released on Dec 09, 2022 by H.C. Wainwright company, set a price target of $56.00, which represents a 33.46% increase from the stock price at the time of the forecast ($41.96), and a 380.69% increase from ENTA last price ($11.65).
Enanta Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $11.65 | $11.65 | $11.65 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Enanta Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Enanta Pharmaceuticals's last price of $11.65. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Feb 08, 2023 | Piper Sandler | Overweight | Overweight | Hold |
| Nov 22, 2022 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Jul 29, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 06, 2022 | Evercore ISI | - | Outperform | Upgrade |
Enanta Pharmaceuticals's last stock rating was published by Piper Sandler on Feb 08, 2023. The company gave ENTA a "Overweight" rating, the same as its previous rate.
Enanta Pharmaceuticals Financial Forecast
Enanta Pharmaceuticals Revenue Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $18.00M | $18.93M | $18.89M | $17.80M | $23.59M | $20.32M | - | $18.72M | $27.65M | $23.57M | $21.62M | $20.13M | $31.74M | $23.63M | $18.65M | $27.62M | $52.57M | $51.31M | $44.37M | $39.63M | $69.89M | $67.20M | $57.26M |
| Avg Forecast | $16.43M | $16.08M | $16.23M | $18.90M | $17.93M | $17.44M | $16.09M | $21.95M | $17.49M | $18.19M | $19.04M | $23.55M | $23.13M | $20.65M | $20.67M | $27.37M | $26.34M | $21.86M | $24.38M | $27.73M | $25.55M | $26.32M | $30.05M | $58.07M | $55.94M | $46.98M | $40.88M | $75.48M | $61.52M | $57.85M |
| High Forecast | $17.77M | $17.40M | $17.56M | $20.45M | $19.15M | $18.87M | $17.41M | $22.75M | $33.07M | $19.68M | $20.61M | $25.48M | $25.03M | $20.65M | $23.84M | $31.56M | $30.37M | $25.21M | $28.11M | $31.98M | $29.47M | $30.35M | $34.65M | $66.97M | $64.52M | $54.18M | $47.15M | $90.57M | $73.83M | $69.42M |
| Low Forecast | $14.75M | $14.44M | $14.58M | $16.97M | $17.13M | $15.66M | $14.45M | $21.13M | $7.85M | $16.34M | $17.10M | $21.15M | $20.77M | $20.65M | $17.15M | $22.71M | $21.85M | $18.14M | $20.23M | $23.01M | $21.20M | $21.84M | $24.93M | $48.19M | $46.42M | $38.98M | $33.92M | $60.38M | $49.22M | $46.28M |
| # Analysts | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 2 | 7 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 16 | 20 |
| Surprise % | - | - | - | - | - | - | - | 0.82% | 1.08% | 1.04% | 0.93% | 1.00% | 0.88% | - | 0.91% | 1.01% | 0.90% | 0.99% | 0.83% | 1.14% | 0.92% | 0.71% | 0.92% | 0.91% | 0.92% | 0.94% | 0.97% | 0.93% | 1.09% | 0.99% |
Enanta Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $16.09M, with a low forecast of $14.45M, and a high forecast of $17.41M. ENTA's average Quarter revenue forecast represents a -10.61% decrease compared to the company's last Quarter revenue of $18.00M (Dec 23).
Enanta Pharmaceuticals EBITDA Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 2 | 7 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 16 | 20 |
| EBITDA | - | - | - | - | - | - | - | $-29.95M | $-25.70M | $-36.71M | $-39.45M | $-30.01M | $-26.39M | - | $-33.02M | $-29.37M | $-32.59M | $-32.59M | $-27.78M | $-10.75M | $-17.73M | $-20.49M | $-7.06M | $17.93M | $9.60M | $7.05M | $1.74M | $30.42M | $36.54M | $24.64M |
| Avg Forecast | $-10.38M | $-10.16M | $-10.26M | $-11.95M | $-11.34M | $-11.03M | $-45.11M | $-13.87M | $-11.06M | $-11.50M | $-35.66M | $-14.89M | $-35.85M | $-13.06M | $-28.19M | $-20.27M | $-32.59M | $-37.67M | $-24.66M | $-13.99M | $-9.03M | $-23.66M | $-10.57M | $14.67M | $11.23M | $5.10M | $7.06M | $32.67M | $33.16M | $24.89M |
| High Forecast | $-9.32M | $-9.13M | $-9.21M | $-10.73M | $-10.83M | $-9.90M | $-36.08M | $-13.36M | $-4.96M | $-10.33M | $-28.53M | $-13.37M | $-28.68M | $-13.06M | $-22.55M | $-16.22M | $-26.07M | $-30.14M | $-19.73M | $-11.19M | $-7.22M | $-18.93M | $-8.45M | $17.60M | $13.47M | $6.12M | $8.47M | $39.21M | $39.80M | $29.86M |
| Low Forecast | $-11.24M | $-11.00M | $-11.10M | $-12.93M | $-12.11M | $-11.93M | $-54.13M | $-14.38M | $-20.91M | $-12.44M | $-42.79M | $-16.11M | $-43.02M | $-13.06M | $-33.82M | $-24.33M | $-39.11M | $-45.20M | $-29.59M | $-16.79M | $-10.84M | $-28.39M | $-12.68M | $11.73M | $8.98M | $4.08M | $5.65M | $26.14M | $26.53M | $19.91M |
| Surprise % | - | - | - | - | - | - | - | 2.16% | 2.32% | 3.19% | 1.11% | 2.02% | 0.74% | - | 1.17% | 1.45% | 1.00% | 0.87% | 1.13% | 0.77% | 1.96% | 0.87% | 0.67% | 1.22% | 0.85% | 1.38% | 0.25% | 0.93% | 1.10% | 0.99% |
4 analysts predict ENTA's average Quarter EBITDA for Mar 20 to be $-10.57M, with a high of $-8.45M and a low of $-12.68M. This is -158.94% lower than Enanta Pharmaceuticals's previous annual EBITDA (Dec 19) of $17.93M.
Enanta Pharmaceuticals Net Income Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 2 | 7 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 16 | 20 |
| Net Income | - | - | - | - | - | - | - | $-33.41M | $-28.11M | $-39.06M | $-37.66M | $-28.99M | $-26.35M | - | $-33.34M | $-30.11M | $-24.60M | $-24.02M | $-22.05M | $-8.33M | $-29.34M | $-14.27M | $-6.00M | $13.44M | $9.19M | $7.04M | $4.14M | $26.01M | $27.42M | $20.29M |
| Avg Forecast | $-30.61M | $-29.55M | $-27.96M | $-23.19M | $-24.58M | $-30.34M | $-46.24M | $-25.97M | $-44.99M | $-47.62M | $-36.55M | $-33.31M | $-27.06M | $-29.42M | $-28.89M | $-20.79M | $-24.60M | $-27.77M | $-19.57M | $-10.84M | $-14.95M | $-16.47M | $-8.99M | $11.00M | $10.75M | $5.09M | $16.79M | $27.94M | $24.89M | $20.50M |
| High Forecast | $-26.54M | $-25.63M | $-24.25M | $-20.11M | $-14.84M | $-26.31M | $-36.99M | $-23.55M | $-25.87M | $-41.31M | $-29.24M | $-28.89M | $-21.65M | $-29.42M | $-23.12M | $-16.63M | $-19.68M | $-22.22M | $-15.66M | $-8.67M | $-11.96M | $-13.18M | $-7.19M | $13.20M | $12.90M | $6.10M | $20.14M | $33.53M | $29.86M | $24.59M |
| Low Forecast | $-33.87M | $-32.70M | $-30.94M | $-25.66M | $-31.79M | $-33.57M | $-55.48M | $-29.71M | $-52.87M | $-52.70M | $-43.86M | $-36.86M | $-32.47M | $-29.42M | $-34.67M | $-24.94M | $-29.52M | $-33.33M | $-23.48M | $-13.01M | $-17.94M | $-19.77M | $-10.78M | $8.80M | $8.60M | $4.07M | $13.43M | $22.35M | $19.91M | $16.40M |
| Surprise % | - | - | - | - | - | - | - | 1.29% | 0.62% | 0.82% | 1.03% | 0.87% | 0.97% | - | 1.15% | 1.45% | 1.00% | 0.87% | 1.13% | 0.77% | 1.96% | 0.87% | 0.67% | 1.22% | 0.85% | 1.38% | 0.25% | 0.93% | 1.10% | 0.99% |
Enanta Pharmaceuticals's average Quarter net income forecast for Mar 20 is $-8.99M, with a range of $-10.78M to $-7.19M. ENTA's average Quarter net income forecast represents a -166.85% decrease compared to the company's last Quarter net income of $13.44M (Dec 19).
Enanta Pharmaceuticals SG&A Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 2 | 7 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 16 | 20 |
| SG&A | - | - | - | - | - | - | - | $16.52M | $13.79M | $12.62M | $13.78M | $12.70M | $12.57M | - | $10.48M | $9.51M | $8.36M | $8.48M | $8.33M | $7.38M | $6.73M | $6.82M | $6.88M | $6.92M | $6.16M | $6.15M | $6.78M | $7.15M | $5.83M | $6.13M |
| Avg Forecast | $6.18M | $6.05M | $6.11M | $7.11M | $6.75M | $6.57M | $14.42M | $8.26M | $6.58M | $6.85M | $11.40M | $8.87M | $9.19M | $7.77M | $9.01M | $6.56M | $8.36M | $9.80M | $7.39M | $9.60M | $3.43M | $7.88M | $10.30M | $5.66M | $7.21M | $4.45M | $27.46M | $7.68M | $5.29M | $6.20M |
| High Forecast | $6.69M | $6.55M | $6.61M | $7.70M | $7.21M | $7.10M | $17.30M | $8.56M | $12.45M | $7.41M | $13.68M | $9.59M | $11.03M | $7.77M | $10.81M | $7.88M | $10.03M | $11.76M | $8.87M | $11.52M | $4.11M | $9.45M | $12.36M | $6.80M | $8.65M | $5.34M | $32.95M | $9.22M | $6.35M | $7.44M |
| Low Forecast | $5.55M | $5.43M | $5.49M | $6.39M | $6.45M | $5.90M | $11.54M | $7.95M | $2.95M | $6.15M | $9.12M | $7.96M | $7.35M | $7.77M | $7.21M | $5.25M | $6.68M | $7.84M | $5.91M | $7.68M | $2.74M | $6.30M | $8.24M | $4.53M | $5.77M | $3.56M | $21.97M | $6.15M | $4.23M | $4.96M |
| Surprise % | - | - | - | - | - | - | - | 2.00% | 2.10% | 1.84% | 1.21% | 1.43% | 1.37% | - | 1.16% | 1.45% | 1.00% | 0.87% | 1.13% | 0.77% | 1.96% | 0.87% | 0.67% | 1.22% | 0.85% | 1.38% | 0.25% | 0.93% | 1.10% | 0.99% |
Enanta Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $14.42M, based on 1 Wall Street analysts, with a range of $11.54M to $17.30M. The forecast indicates a -12.71% fall compared to ENTA last annual SG&A of $16.52M (Dec 23).
Enanta Pharmaceuticals EPS Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 2 | 7 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 16 | 20 |
| EPS | - | - | - | - | - | - | - | $-1.58 | $-1.34 | $-1.86 | $-1.79 | $-1.39 | $-1.28 | - | $-1.62 | $-1.48 | $-1.22 | $-1.19 | $-1.09 | $-0.41 | $-1.46 | $-0.71 | $-0.30 | $0.68 | $0.47 | $0.36 | $0.21 | $1.34 | $1.41 | $1.05 |
| Avg Forecast | $-1.45 | $-1.40 | $-1.32 | $-1.09 | $-1.16 | $-1.43 | $-1.34 | $-1.23 | $-2.12 | $-2.25 | $-1.96 | $-1.57 | $-1.25 | $-1.39 | $-1.42 | $-1.10 | $-1.21 | $-1.32 | $-0.98 | $-0.77 | $-0.89 | $-0.84 | $-0.75 | $0.55 | $0.53 | $0.16 | $-0.06 | $1.45 | $1.08 | $0.99 |
| High Forecast | $-1.25 | $-1.21 | $-1.14 | $-0.95 | $-0.70 | $-1.24 | $-1.16 | $-1.11 | $-1.22 | $-1.95 | $-1.70 | $-1.36 | $-1.09 | $-1.39 | $-1.11 | $-0.86 | $-0.94 | $-1.02 | $-0.77 | $-0.60 | $-0.70 | $-0.66 | $-0.59 | $0.66 | $0.63 | $0.20 | $-0.05 | $1.74 | $1.30 | $1.19 |
| Low Forecast | $-1.60 | $-1.54 | $-1.46 | $-1.21 | $-1.50 | $-1.59 | $-1.48 | $-1.40 | $-2.50 | $-2.49 | $-2.17 | $-1.74 | $-1.39 | $-1.39 | $-1.71 | $-1.32 | $-1.45 | $-1.58 | $-1.18 | $-0.92 | $-1.07 | $-1.01 | $-0.90 | $0.43 | $0.41 | $0.13 | $-0.07 | $1.16 | $0.86 | $0.79 |
| Surprise % | - | - | - | - | - | - | - | 1.29% | 0.63% | 0.83% | 0.91% | 0.88% | 1.02% | - | 1.14% | 1.34% | 1.01% | 0.90% | 1.11% | 0.53% | 1.64% | 0.84% | 0.40% | 1.24% | 0.89% | 2.21% | -3.61% | 0.92% | 1.31% | 1.06% |
According to 4 Wall Street analysts, Enanta Pharmaceuticals's projected average Quarter EPS for Mar 20 is $-0.75, with a low estimate of $-0.90 and a high estimate of $-0.59. This represents a -210.50% decrease compared to ENTA previous annual EPS of $0.68 (Dec 19).
Enanta Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | $1.66 | $20.00 | 1104.82% | Buy |
| KRON | Kronos Bio | $0.94 | $7.63 | 711.70% | Buy |
| LYEL | Lyell Immunopharma | $1.39 | $9.50 | 583.45% | Hold |
| ENTA | Enanta Pharmaceuticals | $11.65 | $65.67 | 463.69% | Buy |
| HOWL | Werewolf Therapeutics | $2.23 | $12.00 | 438.12% | Buy |
| EWTX | Edgewise Therapeutics | $18.08 | $48.00 | 165.49% | Buy |
| MLYS | Mineralys Therapeutics | $11.98 | $30.00 | 150.42% | Buy |
| STOK | Stoke Therapeutics | $15.12 | $33.75 | 123.21% | Buy |
| CGEM | Cullinan Oncology | $17.24 | $32.00 | 85.61% | Buy |
| CCCC | C4 Therapeutics | $6.46 | $11.33 | 75.39% | Hold |
| DSGN | Design Therapeutics | $5.77 | $9.67 | 67.59% | Buy |
| MRUS | Merus | $50.10 | $77.86 | 55.41% | Buy |
| CRNX | Crinetics Pharmaceuticals | $52.99 | $70.14 | 32.36% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.77 | $52.17 | 19.19% | Buy |
| IKNA | Ikena Oncology | $1.67 | $1.33 | -20.36% | Buy |
ENTA Forecast FAQ
Is Enanta Pharmaceuticals a good buy?
Yes, according to 3 Wall Street analysts, Enanta Pharmaceuticals (ENTA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of ENTA's total ratings.
What is ENTA's price target?
Enanta Pharmaceuticals (ENTA) average price target is $65.67 with a range of $54 to $87, implying a 463.69% from its last price of $11.65. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Enanta Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for ENTA stock, the company can go up by 463.69% (from the last price of $11.65 to the average price target of $65.67), up by 646.78% based on the highest stock price target, and up by 363.52% based on the lowest stock price target.
Can Enanta Pharmaceuticals stock reach $20?
ENTA's average twelve months analyst stock price target of $65.67 supports the claim that Enanta Pharmaceuticals can reach $20 in the near future.
What are Enanta Pharmaceuticals's analysts' financial forecasts?
Enanta Pharmaceuticals's analysts financial forecasts for the fiscal year (Sep 2024) are as follows: average revenue is $73.42M (high $78.19M, low $68.37M), average EBITDA is $-81.345M (high $-70.174M, low $-92.547M), average net income is $-127M (high $-102M, low $-151M), average SG&A $36M (high $40.18M, low $31.83M), and average EPS is $-5.155 (high $-4.214, low $-5.967). ENTA's analysts financial forecasts for the fiscal year (Sep 2025) are as follows: average revenue is $67.64M (high $73.18M, low $60.73M), average EBITDA is $-42.758M (high $-38.394M, low $-46.264M), average net income is $-111M (high $-96.533M, low $-123M), average SG&A $25.46M (high $27.55M, low $22.86M), and average EPS is $-5.255 (high $-4.558, low $-5.815).
Did the ENTA's actual financial results beat the analysts' financial forecasts?
Based on Enanta Pharmaceuticals's last annual report (Sep 2023), the company's revenue was $79.2M, beating the average analysts forecast of $78.28M by 1.18%. Apple's EBITDA was $-137M, beating the average prediction of $-73.105M by 87.68%. The company's net income was $-134M, missing the average estimation of $-162M by -17.64%. Apple's SG&A was $52.89M, beating the average forecast of $33.7M by 56.95%. Lastly, the company's EPS was $-6.38, missing the average prediction of $-7.909 by -19.33%. In terms of the last quarterly report (Dec 2023), Enanta Pharmaceuticals's revenue was $18M, missing the average analysts' forecast of $21.95M by -17.97%. The company's EBITDA was $-29.946M, beating the average prediction of $-13.874M by 115.84%. Enanta Pharmaceuticals's net income was $-33.407M, beating the average estimation of $-25.967M by 28.65%. The company's SG&A was $16.52M, beating the average forecast of $8.26M by 99.96%. Lastly, the company's EPS was $-1.58, beating the average prediction of $-1.226 by 28.87%